BSGI Demonstrates Improved Specificity in Detecting Breast Cancer When
Compared to Magnetic Resonance Imaging (MRI)
CHICAGO, Nov. 29 /PRNewswire/ -- Results presented today from a
prospective study to evaluate Breast-Specific Gamma Imaging (BSGI) in the
detection of breast cancer support the potential of BSGI as a tool to improve
breast cancer detection as well as reduce the number of benign biopsies,
according to the study authors. This study, performed by Dr. Rachel Brem and
colleagues at the George Washington University Medical Center, was presented
today at the annual meeting of the Radiology Society of North American (RSNA).
BSGI is a nuclear medicine procedure that images the metabolic activity of
breast lesions through radiotracer uptake, specifically imaged using a
high-resolution, small field-of-view gamma camera.
"We undertook this study to compare the sensitivity and specificity of
BSGI with magnetic resonance imaging (MRI) in patients with abnormal
mammographic findings," said Dr. Rachel Brem, of George Washington University
Medical Center.
In the study, both MRI and BSGI were used in 20 women with 29 lesions.
The BSGI and MRI images were independently interpreted and the findings were
compared. Lesions underwent biopsy or surgical excisions and the pathology
was correlated; 28 of the 29 lesions were confirmed via pathology. Breast
cancer was found in 8/29 (28 percent) of the lesions, while 20/29 (72 percent)
were found to be benign.
The findings indicate both BSGI and MRI are highly sensitive in detecting
lesions, with sensitivities of 89 and 100 percent, respectively. However, the
two approaches demonstrated significant differences in specificity with
specificity of 68 percent for BSGI, and 23 percent for MRI.
"BSGI provides an equivalent sensitivity and improved specificity when
compared to MRI in detecting malignant tumors in the breast," according to Dr.
Brem. "This technology may provide a means to improve breast cancer detection
and reduce the number of benign biopsies. However, due to the small number of
patients, larger studies are needed to further compare BSGI with MRI."
Dilon Technologies, LLC is bringing innovative new medical products to
market based on research conducted at leading national research laboratories.
Recognizing the immediate need for adjunctive diagnostic tools to mammography
for early breast cancer detection, the company's first offering is the Dilon
6800 Gamma Camera -- optimized for breast imaging.
BSGI is a molecular breast imaging technique that has proven to be an
effective tool in the early detection of breast cancer and in the
differentiation of malignant and benign tumors. Better than its predecessor,
scintimammography, BSGI relies on the advanced imaging technology of
anatomic-specific detectors and superior positioning to optimize the results
of functional breast imaging.
Several leading medical centers around the country are now offering BSGI
to their patients. These centers include: Beth Israel Medical Center, New
York; George Washington Medical Center, Washington, D.C.; Alexian Brothers
Medical Center, Chicago; West Houston Medical Center, Houston; Breast Health
Institute, Orlando; and West Valley Imaging, Las Vegas.
For more information, visit the company's website: http://www.dilon.com .
SOURCE Dilon Technologies, LLC
 back to top
Related links:
http://www.dilon.com
CONTACT:
Nancy Morter of Dilon Technologies, LLC,
+1-757-269-4910, or nfmorter@dilon.com
|
